In this research article from Journal of Comparative Effectiveness Research, a new network meta-analysis compares lurasidone and brexpiprazole in acute schizophrenia.
Low levels of vasopressin may be linked to low social ability in monkeys and autism in children, indicating that the hormone could be a biomarker for autism.
In this week’s industry news round-up, we’ve chosen the latest updates from a wide range of disorders extending from depression to multiple sclerosis.
A new study has revealed that a nasal spray formulation of ketamine demonstrates promise in the rapid treatment of symptoms of major depression and suicidal thoughts.
In this week’s round-up, we cover the latest industry news from depression and Parkinson’s disease. Find out more about our selection of the highlights this week.
A recent study has reported that long-term consumption of caffeine has negative effects for Alzheimer’s disease, potentially worsening the neuropsychiatric symptoms in those affected by the disorder.
Antidepressants are an effective treatment route for depression, novel study claims.
Researchers from Queensland University of Technology have identified a drug that could reverse the damaging effects of heavy alcohol consumption on neurogenesis.
Balovaptan, a molecule being developed by Roche for autism spectrum disorder, has been given FDA approval in order to accelerate its development.
This case report from Neurodegenerative Disease Management examines the suicide of a patient with early-onset Alzheimer’s disease in the context of planned versus impulsive acts in cognitive disorders.